Champions Oncology
Champions Oncology, a leading player in the biotechnology industry, is headquartered in China (CN) and operates extensively across North America and Europe. Founded in 2010, the company has made significant strides in advancing personalised cancer treatment through its innovative technology platforms. Specialising in the development of patient-derived xenograft (PDX) models, Champions Oncology offers unique solutions that enable oncologists to tailor therapies based on individual tumour characteristics. This approach not only enhances treatment efficacy but also optimises patient outcomes. With a strong market position, Champions Oncology has garnered recognition for its contributions to cancer research and personalised medicine, solidifying its reputation as a trusted partner in the fight against cancer.
DitchCarbon Score
How does Champions Oncology's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Champions Oncology's score of 4 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Champions Oncology's reported carbon emissions
Champions Oncology, headquartered in CN, has set ambitious climate commitments aimed at significantly reducing its greenhouse gas emissions. Although specific emissions data for the most recent year is not available, the company has established a target to reduce its Scope 1 and Scope 2 emissions by 42% by 2030, using 2020 as the baseline year. This target has been validated through a streamlined process for small and medium-sized enterprises (SMEs) and aligns with the necessary reductions to limit global warming to 1.5°C. In addition to its Scope 1 and Scope 2 commitments, Champions Oncology is also focused on measuring and reducing its Scope 3 emissions, which encompass indirect emissions from its value chain. These initiatives reflect the company's dedication to sustainability and its proactive approach to addressing climate change within the pharmaceuticals, biotechnology, and life sciences sector.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Champions Oncology is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
